[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340028-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340028-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prpc-controls-epithelial-to-mesenchymal-transition-in-egfr-mutated-nsclc-implications-for-tki-resistance-and-patient-follow-up","PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up","","Patients with EGFR-mutated non-small cell lung cancer (NSCLC) benefit from EGFR-targeted tyrosine kinase inhibitors (TKIs), yet relapse occurs in all patients despite treatment improvements. Epithelial-to-mesenchymal transition (EMT) remains incompletely defined as a driver of resistance. This study tests whether the cellular prion protein PrPC regulates EMT and EGFR-TKI resistance in NSCLC. Using multiple datasets, functional cell-line manipulation, mechanistic ILK-RBPJ signaling, and longitudinal patient plasma analyses, PrPC is identified as an EMT-linked resistance candidate and a non-invasive follow-up biomarker.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prpc-controls-epithelial-to-mesenchymal-transition-in-egfr-mutated-nsclc-implications-for-tki-resistance-and-patient-follow-up/340028/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prpc-controls-epithelial-to-mesenchymal-transition-in-egfr-mutated-nsclc-implications-for-tki-resistance-and-patient-follow-up/340028.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is relapse common in EGFR-mutated NSCLC even with EGFR-targeted TKIs?","Question",{"text":63,"@type":64},"All patients with EGFR mutations eventually develop TKI resistance. The paper highlights multiple resistance processes, including EMT features observed in relapsed disease and drug-tolerant states.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What evidence links PrPC to EMT in EGFR-mutated NSCLC?",{"text":68,"@type":64},"Across five independent lung adenocarcinoma datasets, PRNP expression correlates with EMT. Functional manipulation in EGFR-mutated NSCLC cell lines shows PrPC is required to maintain or acquire a mesenchymal phenotype.",{"name":70,"@type":61,"acceptedAnswer":71},"How does PrPC contribute mechanistically to EGFR-TKI resistance?",{"text":72,"@type":64},"The study shows PrPC acts through an ILK-RBPJ cascade that also controls EGFR expression. Elevated PrPC levels occur in EGFR-mutated tumors and after EGFR activation in vitro, with PRNP increasing alongside TKI resistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340028,1790193859,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Oncogene [www.nature.com/onc](www.nature.com/onc)  \nARTICLE OPEN   \nPrPC controls epithelial-to-mesenchymal transition in EGFRmutated NSCLC: implications for TKI resistance and patient follow-up  \nClaire Lailler 1, Audrey Didelot1,10, Simon Garinet1,10, Hugo Berthou1, Marine Sroussi 1,2, Aurélien de Reyniès 1, Shoukat Dedhar3, Séverine Martin-Lannerée 1, Elizabeth Fabre4, Françoise Le Pimpec-Barthes5, Alexandre Perrier1, Virginie Poindessous 1, Audrey Mansuet-Lupo6, Fatima Djouadi 1, Jean-Marie Launay 7,8, Pierre Laurent-Puig 1,2, Hélène Blons1,9,10 ✉ and  \nSophie Mouillet-Richard 1,10 ✉  \n© The Author(s) 2024  \n\n| | Patients with EGFR-mutated non-small cell lung cancer (NSCLC) beneﬁt from treatment with tyrosine kinase inhibitors (TKI) targeting EGFR. Despite improvements in patient care, especially with the 3rd generation TKI osimertinib, disease relapse is observed in all patients. Among the various processes involved in TKI resistance, epithelial-to-mesenchymal transition (EMT) is far from being fully characterized. We hypothesized that the cellular prion protein PrPC could be involved in EMT and EGFR-TKI resistance in NSCLC. Using 5 independent lung adenocarcinoma datasets, including our own cohort, we document that the expression of the PRNP gene encoding PrPC is associated with EMT. By manipulating the levels of PrPC in different EGFR-mutated NSCLC cell lines, we ﬁrmly establish that the expression of PrPC is mandatory for cells to maintain or acquire a mesenchymal phenotype. Mechanistically, we show that PrPC operates through an ILK-RBPJ cascade, which also controls the expression of EGFR. Our data further demonstrate that PrPC levels are elevated in EGFR-mutated versus wild-type tumours or upon EGFR activation in vitro. In addition, we provide evidence that PRNP levels increase with TKI resistance and that reducing PRNP expression sensitizes cells to osimertinib. Finally, we found that plasma PrPC levels are increased in EGFR-mutated NSCLC patients from 2 independent cohorts and that their longitudinal evolution mirrors that of disease. Altogether, these ﬁndings deﬁne PrPC as a candidate driver of EMT-dependent resistance to EGFR-TKI in NSCLC. They further suggest that monitoring plasma PrPC levels may represent a valuable non-invasive strategy for patient follow-up and warrant considering PrPC-targeted therapies for EGFR-mutated NSCLC patients with TKI failure.\u003Cbr>Oncogene (2024) 43:2781–2794; [https://doi.org/10.1038/s41388-024-03130-0](https://doi.org/10.1038/s41388-024-03130-0) | |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| |  | |\n\nGraphical Abstract  \nA full list of author afﬁliations appears at the end of the paper.  \nReceived: 23 May 2024 Revised: 2 August 2024 Accepted: 7 August 2024  \nPublished online: 15 August 2024  \nC. Lailler et al.  \n2782  \nINTRODUCTION  \nLung cancer remains the deadliest cancer worldwide with 1.8 million deaths in 2020, representing 18% of the overall cancerrelated deaths [1] . Because the majority of cases are detected at late stages, either non-resectable or metastatic diseases at diagnosis, the 5-year survival rate for non-small cell lung cancer (NSCLC), the most common subtype, remains beyond 25% and drops below 5% for stage 4 disease ([https://seer.cancer.gov/](https://seer.cancer.gov/)[ ](https://seer.cancer.gov/)[statfacts/html/lungb.html](statfacts/html/lungb.html)) . Advances in the molecular characterization of NSCLC tumours have led to the identiﬁcation of targetable genomic alterations, among which EGFR mutations are the most frequently encountered, occurring in 15–25% of cases in Caucasians, and up to 40 to 55% cases in East Asians [2] . Despite the advent of tyrosine kinase inhibitors (TKI) targeting mutant EGFR, including the third generation TKI osimertinib, all patients bearing EGFR mutations eventually develop resistance, typic","cbCainTxmVUGIU20","https://ap.wps.com/l/cbCainTxmVUGIU20","pdf",5641374,14,"English","# Introduction\n## EMT and EGFR-TKI resistance in NSCLC\n## PrPC as a contributor to EMT\n## Study aim and approach","[{\"question\":\"Why is relapse common in EGFR-mutated NSCLC even with EGFR-targeted TKIs?\",\"answer\":\"All patients with EGFR mutations eventually develop TKI resistance. The paper highlights multiple resistance processes, including EMT features observed in relapsed disease and drug-tolerant states.\"},{\"question\":\"What evidence links PrPC to EMT in EGFR-mutated NSCLC?\",\"answer\":\"Across five independent lung adenocarcinoma datasets, PRNP expression correlates with EMT. Functional manipulation in EGFR-mutated NSCLC cell lines shows PrPC is required to maintain or acquire a mesenchymal phenotype.\"},{\"question\":\"How does PrPC contribute mechanistically to EGFR-TKI resistance?\",\"answer\":\"The study shows PrPC acts through an ILK-RBPJ cascade that also controls EGFR expression. Elevated PrPC levels occur in EGFR-mutated tumors and after EGFR activation in vitro, with PRNP increasing alongside TKI resistance.\"}]","PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up | PDF",1790033823,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0fd23f3f3ba7dfbffdf40d915b0c2fcb.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3726811cb351ba9dabba95be2ec4b13f.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5fa1e90c6757589a7babe4db5164742f.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a59d217cb4b886180d5447d9398d03e.webp",980,1301]